Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Boryung Pharmaceutical has added Eli Lily's Gemzar among the anti-cancer drugs that it has rights to distribute in South Korea.
Boryung also has distribution rights to such anti-cancer drugs as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
Boryung CEO Ahn Jae-hyun promised to continue growing its anti-cancer portfolio as the company's focal point.
Gemzar (gemcitabine), a nucleoside metabolic inhibitor, is mainly a pancreatic cancer treatment drug.
Combined with other drugs, Gemzar is used for the treatment of metastatic breast cancer, advanced ovarian cancer, and non-small cell lung cancer.
Gemzar posted 14.2 billion won in revenue in South Korea last year.
